Hyderabad-based Bharat Biotech International Ltd set a precedent in the arena of diabetic foot care, burn injuries and skin grafts by launching therapeutic, REGEN-D, a recombinant epidermal growth factor (rhEGF). Dr NK Ganguly, director general, Indian Council of Medical Research formally launched the country’s first rhEGF, indigenously developed, and manufactured by Bharat Biotech, in Chennai. “REGEN-D is the result of a unique public-private technology collaboration. Bharat Biotech has developed this extraordinary therapeutic REGEN-D in collaboration with the Institute of Genomics and Integrated Biology (IGIB), a CSIR institution, New Delhi,” remarked Dr Ganguly.

REGEN-D is being launched in two strengths – REGEN-D 150 for diabetic foot ulcers and REGEN-D 60 for burns and skin grafts.

Dr Krishna M Ella, chairman and managing director, Bharat Biotech said, “REGEN-D 150 manufactured indigenously will tremendously impact the lives of a vast patient population in affected with diabetic foot ulcers and REGEN-D 60 has a great role to play in the burns care.”